ALPHA3: A Pivotal Phase 2 Study of Firstโ€‘Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘Cel) in Patients (Pts)  With Large Bโ€‘Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Continue ReadingALPHA3: A Pivotal Phase 2 Study of Firstโ€‘Line (1L) Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘Cel) in Patients (Pts)  With Large Bโ€‘Cell Lymphoma (LBCL) and Minimal Residual Disease (MRD)  After Response to Standard Therapy

Allogeneic Chimeric Antigen Receptor Tโ€‘Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large Bโ€‘Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingAllogeneic Chimeric Antigen Receptor Tโ€‘Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large Bโ€‘Cell Lymphoma: Phase I Experience From the ALPHA2/ALPHA Clinical Studies

Supplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Continue ReadingSupplementary Appendix: Allogeneic CAR T Cell Products Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory LargeB-Cell Lymphoma: Phase 1 Experience From the ALPHA2/ALPHA Clinical Studies

Alpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘Cel) in Patients With Large Bโ€‘Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Continue ReadingAlpha3: A Pivotal Phase 2 Study of First-Line Consolidation With Cemacabtagene Ansegedleucel (Cemaโ€‘Cel) in Patients With Large Bโ€‘Cell Lymphoma and Minimal Residual Disease After Response to Standard Therapy

Presentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naรฏve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Continue ReadingPresentation, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naรฏve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Poster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naรฏve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)

Continue ReadingPoster, Durable Responses Achieved with Anti-CD19 Allogeneic CAR T ALLO-501/501A in Phase 1 Trials of Autologous CAR T-Naรฏve Patients with Relapsed/Refractory Large B-Cell Lymphoma (r/r LBCL)